Effect of ELX/TEZ/IVA on infections and antibiotic use in cystic fibrosis.

Rapid reduction in infection visits and antibiotic use in people with cystic fibrosis after starting Elexacaftor-Tezacaftor-Ivacaftor.

In the article at the link, you can read about the study of the effectiveness of ELX/TEZ/IVA (or Tricaft) in cystic fibrosis.

This article presents the results of a real-world study of the effectiveness of the triple combination of CFTR modulators — elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) — in patients with cystic fibrosis (CF).

Key aspects of the study:

Problem: Patients with cystic fibrosis suffer from recurrent respiratory infections that require frequent prescription of antimicrobial drugs and are often caused by multidrug-resistant microorganisms.

Objective: To determine the real-world effectiveness of ELX/TEZ/IVA in reducing the number of visits to the doctor for infections and the use of antimicrobial drugs.

Methodology: Retrospective analysis of data from 389 CF patients who started ELX/TEZ/IVA therapy by December 2019, comparing pre- and post-treatment scores for 15 weeks.

Key findings: There were significant reductions in total physician visits, hospitalizations, infection visits, and antibiotic prescriptions over the 15-week period.

Significance: Given that ELX/TEZ/IVA is effective in approximately 90% of people with CF, this therapy could have a significant impact on reducing respiratory infections and antimicrobial use nationally.

The study demonstrates the rapid and significant effect of CFTR modulator therapy on reducing infectious complications in cystic fibrosis, with important implications for clinical practice and public health.

Detailed research results are presented at the link